<level type="section">
  <num>44-109.02</num>
  <heading>Pre-admission medication management assessment.</heading>
  <text>Within 30 days prior to admission, the ALR shall consult with the prospective resident's healthcare practitioner regarding:</text>
  <level>
    <level>
      <num>(1)</num>
      <text>The prospective resident's current medication profile, including a review of nonprescription drugs;</text>
    </level>
    <level>
      <num>(2)</num>
      <text>Possible adverse interactions;</text>
    </level>
    <level>
      <num>(3)</num>
      <text>Common expected or unexpected side effects; and</text>
    </level>
    <level>
      <num>(4)</num>
      <text>The potential that such medications have to act as chemical restraints.</text>
    </level>
  </level>
  <level>
    <type>annotations</type>
    <level>
      <heading>CREDIT(S)</heading>
      <text>(June 24, 2000, D.C. Law 13-127, ยง 902, 47 DCR 2647.)</text>
    </level>
    <level>
      <heading>HISTORICAL AND STATUTORY NOTES</heading>
      <level>
        <heading>Legislative History of Laws</heading>
        <text>For Law 13-127, see notes following ยง 44-101.01.</text>
      </level>
    </level>
  </level>
</level>
